CTOs on the Move

Southern Veterinary Partners

www.southernvetpartnersllc.com

 
Want to sell your vet hospital? We are a veterinarian-owned and managed network of animal hospitals for veterinarians who wish to sell their veterinary practice. Offering veterinary career opportunities. Call 205-453-4760 today!
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Urology Associates of North texas

Urologist Dallas Texas Medical City Hospital Robotic and Laparoscopic Surgery Prostate and Kidney UANT Urology Associates of North Texas Richard Bevan-Thomas MD enlarged prostate treatment vasectomy incontinence Dallas Plano Mesquite Garland Richardson

LifeSync Corporation

LifeSync Corporation is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Season

Season Health is a food as medicine platform that provides clinical nutrition care, meal recommendations, education, and food delivery to people with chronic conditions such as diabetes and kidney disease.

QueensCare Family Clinics

QueensCare Family Clinics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. QueensCare Family Clinics is based in Los Angeles, CA. You can find more information on QueensCare Family Clinics at www.queenscare.org

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.